Highest-materiality recent filing
Sionna cuts workforce 46%, plans Phase 2a trial for SION-451+SION-2222
Board approved restructuring cutting ~46% of workforce, retaining core clinical capabilities for SION-451 and SION-2222.
Sionna's SION-719 Phase 2a misses sweat chloride endpoint; program halted as add-on
SION-719 Phase 2a missed key endpoint: -1.0 mmol/L placebo-adjusted sweat chloride change (p=0.7); not advancing as add-on to SOC.
Sionna Therapeutics Q1 net loss $26.8M; Phase 2a enrollment completed for SION-719
Net loss of $26.8M for Q1 2026, compared to $16.5M in Q1 2025.
Sionna Q3 net loss $20.3M; starts Phase 2a trial for SION-719; cash runway into 2028
Net loss of $20.3M in Q3 2025 versus $25.4M in Q3 2024; R&D expenses fell to $16.0M from $24.6M due to prior year license charge.
Sionna Therapeutics Q2 net loss $18.1M; positive Phase 1 data for NBD1 stabilizers
Net loss $18.1M in Q2 2025 vs $8.6M in Q2 2024; R&D expenses $15.4M.
Both SION-719 and SION-451 were generally well tolerated with no serious adverse events or discontinuations.
Net loss of $16.5M for Q1 2025, up from $11.8M in Q1 2024; R&D expenses $13.7M vs $10.2M.
Net loss Q4 2024 $15.8M, full year $61.7M vs $47.3M in 2023; R&D spend $57.3M.
Jennifer Fitzpatrick, the Company’s Chief Legal Officer, assumed the additional role of Head of Program Management
Elena Ridloff, the Company’s Chief Financial Officer, assumed the additional role of Chief Business Officer
the employment of Caroline Stark Beer, M.B.A., the Company’s Chief Business Officer, was terminated without cause, effective as of September 15, 2026
Charlotte McKee, the Company’s Chief Medical Officer, assumed the additional role of Head of Research and Development
Max materiality 0.85 · Median 0.60 · Most common event earnings